证券代码：300430 证券简称：诚益通 公告编号：2025-055 北京诚益通控制技术集团股份有限公司 关于实际控制人部分股权解除质押的公告 公司实际控制人保证向公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。本公司及董事会全体成员保证信息披露的内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"本公司"） 近日接到公司实际控制人梁学贤先生的通知，获悉其持有的本公司股份办理了部 分股权解除质押业务，具体事项如下： 一、股份质押的基本情况 | | 是否为控 股股东或 | 本次解 | 占其所 | 占公司 | | 是否为 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 第一大股 | 除质押 | 持股份 | 总股本 | 是否为 | 补充质 | 质押起 | 质押到 | 质权人 | 质押 | | 名称 | 东及其一 | 数量（万 | 比例 | 比例 | 限售股 | 押 | 始日 | 期日 | | 用途 | | ...

资金流向方面，主力资金净流入461.06万元，特大单买入584.22万元，占比5.20%，卖出0.00元，占比 0.00%；大单买入1808.19万元，占比16.08%，卖出1931.35万元，占比17.17%。 分红方面，诚益通A股上市后累计派现8055.38万元。近三年，累计派现3960.21万元。 机构持仓方面，截止2025年9月30日，诚益通十大流通股东中，长城消费增值混合A（200006）位居第 五大流通股东，持股200.00万股，为新进股东。广发聚丰混合A（270005）位居第八大流通股东，持股 133.07万股，为新进股东。广发优势成长股票A（011425）位居第十大流通股东，持股100.79万股，为 新进股东。华夏领先股票（001042）退出十大流通股东之列。 责任编辑：小浪快报 诚益通今年以来股价涨26.38%，近5个交易日涨3.05%，近20日涨6.46%，近60日跌6.81%。 资料显示，北京诚益通控制技术集团股份有限公司位于北京市大兴区生物医药产业基地庆丰西路27号， 成立日期2003年7月22日，上市日期2015年3月19日，公司主营业务涉及提供医药、生物工业自动化控制 系统整体解决 ...

Group 1 - The core viewpoint of the news is that Chengyitong's stock has shown fluctuations in price and trading volume, with a current market value of 5.202 billion yuan and a year-to-date increase of 24.88% [1][2] - As of December 19, the stock price increased by 2.09% to 19.05 yuan per share, with a trading volume of 57.55 million yuan and a turnover rate of 1.18% [1] - The company has experienced a net outflow of 996,200 yuan in principal funds, with large orders accounting for 10.85% of purchases and 12.58% of sales [1] Group 2 - Chengyitong's main business includes providing automation control solutions for the pharmaceutical and biotechnology industries, with revenue contributions of 54.65% from control systems, 28.89% from rehabilitation medical devices, and 16.47% from system equipment and others [2] - The company reported a revenue of 633 million yuan for the first nine months of 2025, a year-on-year decrease of 20.40%, and a net profit attributable to shareholders of 67.83 million yuan, down 30.83% year-on-year [2] - The number of shareholders as of September 30, 2025, was 32,000, a decrease of 1.94% from the previous period, with an average of 8,110 circulating shares per person, an increase of 1.98% [2] Group 3 - Chengyitong has distributed a total of 80.55 million yuan in dividends since its A-share listing, with 39.60 million yuan distributed in the last three years [3] - As of September 30, 2025, new institutional shareholders include Changcheng Consumption Value Mixed A, holding 2 million shares, and Guangfa Jufeng Mixed A, holding 1.33 million shares, while Huaxia Leading Stock has exited the top ten circulating shareholders [3]

Core Viewpoint - The A-share market's industrial hemp concept stocks have shown strong performance, with notable gains in several companies, driven by potential regulatory changes in the U.S. regarding cannabis classification [1][2]. Company Performance - Shunhao Co., Ltd. (002565) reached a limit-up with a 10% increase, total market value at 16.9 billion [2]. - Fuan Pharmaceutical (300194) rose by 4.91%, with a market cap of 5.592 billion [2]. - Blue Sky Technology (300487) increased by 4.85%, total market value at 29.1 billion [2]. - Jinying Co., Ltd. (600232) saw a 4.10% rise, with a market cap of 2.593 billion [2]. - Chengyitong (300430) grew by 3.82%, total market value at 5.117 billion [2]. - Yongji Co., Ltd. (603058) increased by 3.44%, with a market cap of 3.740 billion [2]. - Morning Light Biology (300138) rose by 3.19%, total market value at 6.097 billion [2]. Regulatory Impact - Reports indicate that former President Trump is expected to instruct the government to reclassify cannabis as a lower-risk substance, which could represent a significant shift in U.S. cannabis policy [1][2]. - Discussions have taken place between Trump and industry executives, as well as health officials, regarding this potential reclassification [2]. - The reclassification could facilitate easier buying and selling of cannabis, addressing tax burdens and banking service obstacles for cannabis businesses [2].

Group 1: Industrial Mother Machine Sector - The industrial mother machine sector shows a positive trend with a total index increase of 1.29% to 1754.21 [2] - Key stocks in this sector include: - GuoJi Heavy Industry (601399) with a price of 4.63, up by 9.98% and 42.46% over the past five days [2] - China First Heavy Industries (601106) at 3.42, also up by 9.97% and 13.62% over the last five days [2] - Weihong Co., Ltd. (300508) at 38.12, increasing by 9.29% and 10.05% in five days [2] - Other notable performers include: - Yuhuan CNC (002903) at 24.54, up by 6.70% [2] - Ruineng Technology (603933) at 30.40, with a 5.89% increase [2] Group 2: Brain-Computer Interface Sector - The brain-computer interface sector experienced significant activity, highlighted by the upcoming "Brain Link World, Intelligence Gathering in Shanghai" conference scheduled for December 4-5, 2025 [3] - Key stocks in this sector include: - Dineike (300884) with a price of 16.82, up by 14.34% and 18.09% over the past five days [3] - Nanjing Panda (600775) at 12.55, increasing by 9.99% and 13.78% [3] - Chengyitong (300430) at 18.99, up by 3.94% [3] - Other stocks showing positive movement include: - Beiyikang (920199) at 34.70, up by 3.89% [3] - Innovation Medical (002173) at 22.29, with a 3.05% increase [3]

证券代码：300430 证券简称：诚益通 公告编号：2025-054 北京诚益通控制技术集团股份有限公司 关于为上市公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"诚益通"） 于 2025 年 4 月 23 日召开了第五届董事会第十一次会议，会议审议通过了《关于 预计 2025 年度公司及合并范围内公司申请银行综合授信及项目贷款额度的议案》 《关于预计 2025 年度公司及合并范围内公司担保额度的议案》（公告编号： 2025-020、021），同意公司、子公司及合并报表范围内的子公司、孙公司向银 行及其他金融机构申请合计额度不超过人民币 13.79 亿元的授信等业务，在授权 期限内额度可循环使用，担保总额合计不超过 13.19 亿元。上述议案同时由 2025 年 5 月 15 日召开的 2024 年度股东大会审议通过。 二、融资进展情况 近期，北京诚益通科技有限公司（以下简称"诚益通科技"）与杭州银行股 份有限公司北京分行（以下简称"杭州银行"）签署《杭州银行股份 ...

证券代码：300430 证券简称：诚益通 公告编号：2025-053 北京诚益通控制技术集团股份有限公司 关于为上市公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制技术集团股份有限公司（以下简称"公司"或"诚益通"） 于 2025 年 4 月 23 日召开了第五届董事会第十一次会议，会议审议通过了《关于 预计 2025 年度公司及合并范围内公司申请银行综合授信及项目贷款额度的议案》 《关于预计 2025 年度公司及合并范围内公司担保额度的议案》（公告编号： 2025-020、021），同意公司、子公司及合并报表范围内的子公司、孙公司向银 行及其他金融机构申请合计额度不超过人民币 13.79 亿元的授信等业务，在授权 期限内额度可循环使用，担保总额合计不超过 13.19 亿元。上述议案同时由 2025 年 5 月 15 日召开的 2024 年度股东大会审议通过。 三、被担保人基本情况 1、北京诚益通控制技术集团股份有限公司 公司名称：北京诚益通控制技术集团股份有限公司 成立日期：2003 年 07 月 22 ...

证券代码：300430 证券简称：诚益通 公告编号：2025-052 北京诚益通控制技术集团股份有限公司 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次解除 | 本次解除 | | 占公司 | 情况 | | 情况 | | | 股东名 | 持股数量 | 持股比例 | 质押前质 | 质押后质 | 占其所持股 | 总股本 | | | 未质押股 | | | 称 | （万股） | | 押股份数 量 | 押股份数 量 | 份比例 | 比例 | 已质押股 | 占已质 | 份限售和 | 占未质押 | | | | | | | | | 份限售和 冻结数量 | 押股份 比例 | 冻结数量 | 股份比例 | | | | | | | | | | | （万股） | | | 立威特 | 5120.98 | 18.75% | 5063 | 3513 | 68.60% | 12.87% | 3513 | 100% | 0 | 0% | | 1013.76 | 3.7 ...

Core Insights - The brain engineering sector is leading the market with a rise of 1.05% [1] Company Performance - Aipeng Medical saw a significant increase of 7.51% [1] - Innovation Medical experienced a rise of 4.41% [1] - Century Huatong increased by 3.41% [1] - Chengyitong, Xiangyu Medical, and Sanbo Brain Science all rose by over 2% [1]

Core Viewpoint - The A-share market is experiencing a surge in brain-computer interface concept stocks, driven by the approval of a domestically developed implantable wireless brain-computer interface system entering the special review process by the National Medical Products Administration of China, marking a significant step in the commercialization of this technology in China [1] Group 1: Stock Performance - Aipeng Medical saw a nearly 12% increase in stock price, with a total market value of 40.03 billion and a year-to-date increase of 80.63% [2] - Century Huatong and Innovative Medical both rose over 7%, with market values of 141.1 billion and 10.5 billion respectively, and year-to-date increases of 269.65% and 198.87% [2] - Botao Biological increased by over 5%, with a market value of 6.62 billion and a year-to-date increase of 95.06% [2] - Xiangyu Medical rose over 4%, with a market value of 8.33 billion and a year-to-date increase of 78.19% [2] - Other notable stocks include Sanbo Brain Science, Saily Medical, Dineike, Taihe Technology, and Chengyi Tong, all showing increases of over 3% [1][2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive brain-computer interface product to enter the "green channel" for innovative medical devices in China, indicating a key advancement from clinical validation to market access in this cutting-edge technology field [1]